Eye Movement Desensitization and Reprocessing (EMDR) Group Therapy
BehavioralSessions conducted in groups with one therapist and one co-therapist; each session follows the EMDR standard protocol.
NCT Number: NCT07206381
This study will examine the effects of Eye Movement Desensitization and Reprocessing (EMDR) group therapy on adults who experienced the April 2025 Silivri earthquake in Turkey. Participants will be randomly assigned to either an EMDR intervention group or a waitlist control group. Psychological symptoms will be measured using the PTSD Checklist for DSM-5 (PCL-5), the Depression, Anxiety, and Stress Scale (DASS-21), the Short Form Health Survey (SF-36), and the Pittsburgh Sleep Quality Index (PSQI). Quantitative EEG (QEEG) recordings will also be collected before and after the intervention to assess changes in brain activity related to emotional regulation and trauma processing. The goal of the study is to evaluate whether EMDR produces both clinical and neurophysiological improvements in trauma-exposed individuals.
Trial opening soon.
Get Notified18 year–50 year
All sexes
Interventional
Not applicable
Traumatic experiences often lead to persistent psychological symptoms such as posttraumatic stress, depression, anxiety, and sleep disturbances, which significantly impair quality of life. Eye Movement Desensitization and Reprocessing (EMDR) is an evidence-based intervention for trauma-related disorders, and growing evidence suggests that it may also produce measurable changes in brain activity. This randomized controlled trial will evaluate the effects of EMDR group therapy on both clinical outcomes and neurophysiological markers in adults exposed to the April 2025 Silivri earthquake in Turkey.
Forty participants meeting inclusion criteria will be randomly assigned to either an EMDR intervention group (20 participants) or a waitlist control group (20 participants). The intervention group will receive 5-7 sessions of standardized EMDR group therapy, delivered face-to-face by trained therapists. Quantitative EEG (QEEG) recordings will be collected at baseline and after the intervention to assess changes in spectral power, frontal alpha asymmetry, and coherence patterns. Clinical outcomes will be measured with validated self-report instruments assessing PTSD symptoms, depression, anxiety, stress, sleep quality, and overall health-related quality of life.
This study is designed to test the hypothesis that EMDR group therapy produces significant improvements in both psychological symptoms and EEG biomarkers compared to a waitlist control. By integrating subjective self-report and objective neurophysiological data, the trial aims to provide a comprehensive evaluation of EMDR's therapeutic effects in trauma-exposed populations.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Sessions conducted in groups with one therapist and one co-therapist; each session follows the EMDR standard protocol.
Time frame: Baseline (Pre-intervention, T1; Week 0) and Post-intervention (T2; Week 6, after completion of EMDR intervention)
The PTSD Checklist for DSM-5 (PCL-5) is a 20-item self-report scale measuring the severity of posttraumatic stress disorder symptoms according to DSM-5 criteria. Scores range from 0 to 80, with higher scores indicating more severe PTSD symptoms. Change in total score from baseline (pre-intervention) to post-intervention will be assessed.
Time frame: Baseline (Pre-intervention, T1; Week 0) and Post-intervention (T2; Week 6, after completion of EMDR intervention)
EEG recordings will be collected using the Neuron-Spectrum-5 device according to the international 10-20 system. Power spectral analyses will be performed across frequency bands (delta, theta, alpha, beta, high beta). Changes in absolute and relative power from baseline to post-intervention will be examined.
Time frame: Baseline (Pre-intervention, T1; Week 0) and Post-intervention (T2; Week 6, after completion of EMDR intervention)
The Short Form Health Survey (SF-36) is a 36-item measure of health-related quality of life, covering physical functioning, role limitations, pain, general health, vitality, social functioning, and emotional well-being. Scores range from 0 to 100, with higher scores reflecting better quality of life. Change in domain scores will be assessed from baseline to post-intervention.
Time frame: Baseline (Pre-intervention, T1; Week 0) and Post-intervention (T2; Week 6, after completion of EMDR intervention)
The Depression, Anxiety, and Stress Scale-21 (DASS-21) is a 21-item self-report instrument measuring emotional distress across three subscales (depression, anxiety, stress). Scores range from 0 to 42 for each subscale, with higher scores indicating greater severity. Change in scores will be assessed from baseline to post-intervention.
Time frame: Baseline (Pre-intervention, T1; Week 0) and Post-intervention (T2; Week 6, after completion of EMDR intervention)
The Pittsburgh Sleep Quality Index (PSQI) is a 19-item self-report questionnaire assessing sleep quality and disturbances over the past month. Scores range from 0 to 21, with higher scores indicating poorer sleep quality. Change in total score will be assessed from baseline to post-intervention.
Contact information is provided by the study sponsor or research team.
Çiğdem Kınık, PhD
CONTACT
Önder Kavakçı, MD. Prof Dr
CONTACT
Istanbul Galata University
Other
EMDR Group Therapy for Earthquake-Exposed Trauma Survivors: A Randomized Trial of Psychological and QEEG Outcomes
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06644573
Alzheimer Disease, Alzheimer Disease or Associated Disorder
Aventura, Florida, United States
View Trial DetailsNCT07084233
Anxiety, Anxiety Disorders
Lviv, Ukraine
View Trial DetailsNCT07280065
Anxiety Disorders, Behavior
Aurora, Colorado, United States
View Trial DetailsNCT06993012
Anxiety Disorders, Behavior
College Station, Texas, United States
View Trial Details